Cargando…
FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer
Paclitaxel (PTX) is a common regimen used to treat patients with ovarian cancer. Although approximately 60% of ovarian cancer patients exhibit a pathologic complete response (pCR), approximately 40% of patients appear to be insensitive to PTX adjuvant therapy. Thus, identifying a useful biomarker to...
Autores principales: | Chiu, Hui-Wen, Chang, Jeng-Shou, Lin, Hui-Yu, Lee, Hsun-Hua, Kuei, Chia-Hao, Lin, Che-Hsuan, Huang, Huei-Mei, Lin, Yuan-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209951/ https://www.ncbi.nlm.nih.gov/pubmed/30301218 http://dx.doi.org/10.3390/jcm7100330 |
Ejemplares similares
-
OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer
por: Chiu, Hui-Wen, et al.
Publicado: (2017) -
IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis
por: Zheng, Hui, et al.
Publicado: (2023) -
Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma
por: Zhang, Kainan, et al.
Publicado: (2021) -
Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma
por: Zhang, Kainan, et al.
Publicado: (2022) -
Corrigendum: Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma
por: Zhang, Kainan, et al.
Publicado: (2021)